PD-1/PD-L1抑制剂的临床开发趋势。 - Suppr

Trends in clinical development for PD-1/PD-L1 inhibitors.

作者信息

Xin Yu Jia, Hodge Jeffrey P, Oliva Cristina, Neftelinov Svetoslav T, Hubbard-Lucey Vanessa M, Tang Jun

出版信息

Nat Rev Drug Discov. 2020 Mar;19(3):163-164. doi: 10.1038/d41573-019-00182-w.

DOI:10.1038/d41573-019-00182-w

PMID:32127660

Abstract

摘要

相似文献

Trends in clinical development for PD-1/PD-L1 inhibitors.

Nat Rev Drug Discov. 2020 Mar;19(3):163-164. doi: 10.1038/d41573-019-00182-w.

PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules.

Curr Pharm Des. 2018 Feb 12;23(39):6033-6041. doi: 10.2174/1381612823666171004120152.

Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy.

J Drug Target. 2019 Mar;27(3):244-256. doi: 10.1080/1061186X.2018.1440400. Epub 2018 Feb 20.

[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].

Ann Pathol. 2017 Feb;37(1):61-78. doi: 10.1016/j.annpat.2016.12.009. Epub 2017 Feb 3.

Development of the Inhibitors that Target the PD-1/PD-L1 Interaction-A Brief Look at Progress on Small Molecules, Peptides and Macrocycles.

Molecules. 2019 May 30;24(11):2071. doi: 10.3390/molecules24112071.

Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.

Recent Pat Anticancer Drug Discov. 2019;14(2):100-112. doi: 10.2174/1574892813666181029142812.

Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?

Eur J Med Chem. 2019 Jan 1;161:378-398. doi: 10.1016/j.ejmech.2018.10.044. Epub 2018 Oct 19.

The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials.

Int Immunopharmacol. 2019 Dec;77:105975. doi: 10.1016/j.intimp.2019.105975. Epub 2019 Nov 6.

[PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].

Bull Cancer. 2018 Mar;105(3):263-274. doi: 10.1016/j.bulcan.2017.11.012. Epub 2018 Feb 16.

Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.

J Cancer Res Clin Oncol. 2018 Oct;144(10):1851-1859. doi: 10.1007/s00432-018-2707-4. Epub 2018 Jul 17.

引用本文的文献

Tumor-expressing PD-L1 regulates NT5E expression through MAPK/ERK pathway in triple-negative breast cancer.

Oncol Res. 2025 Jun 26;33(7):1633-1648. doi: 10.32604/or.2025.061637. eCollection 2025.

Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors.

Front Immunol. 2025 Jun 18;16:1583363. doi: 10.3389/fimmu.2025.1583363. eCollection 2025.

Low-cost robotic manipulation of live microtissues for cancer drug testing.

Sci Adv. 2025 May 16;11(20):eads1631. doi: 10.1126/sciadv.ads1631. Epub 2025 May 14.

Inhibition of ENT1 relieves intracellular adenosine-mediated T cell suppression in cancer.

Nat Immunol. 2025 May 12. doi: 10.1038/s41590-025-02153-3.

Ginsenoside Rh2 in combination with IFNγ potentiated the anti-cancer effect by enhancing interferon signaling response in colorectal cancer cells.

Acta Pharmacol Sin. 2025 Apr 22. doi: 10.1038/s41401-025-01557-z.

ICOS+CD4+ T cells define a high susceptibility to anti-PD-1 therapy-induced lung pathogenesis.

JCI Insight. 2025 Apr 8;10(10). doi: 10.1172/jci.insight.186483. eCollection 2025 May 22.

Digging Through the Complexities of Immunological Approaches in Emerging Osteosarcoma Therapeutics: A Comprehensive Narrative Review with Updated Clinical Trials.

Biomedicines. 2025 Mar 8;13(3):664. doi: 10.3390/biomedicines13030664.

Role of tertiary lymphoid structures and B cells in clinical immunotherapy of gastric cancer.

Front Immunol. 2025 Jan 7;15:1519034. doi: 10.3389/fimmu.2024.1519034. eCollection 2024.

In silico exploration of PD-L1 binding compounds: Structure-based virtual screening, molecular docking, and MD simulation.

PLoS One. 2024 Aug 9;19(8):e0306804. doi: 10.1371/journal.pone.0306804. eCollection 2024.

Ovarian cancer: Diagnosis and treatment strategies (Review).

Oncol Lett. 2024 Jul 18;28(3):441. doi: 10.3892/ol.2024.14574. eCollection 2024 Sep.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Trends in clinical development for PD-1/PD-L1 inhibitors.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献